2020ASCO肺癌摘要汇总9500.pptx

  1. 1、本文档共20页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced <br />non-small cell lung cancer: Three-year update from CheckMate 227 Part 1 ;Introduction;CheckMate 227a Part 1 study design;Baseline characteristics: CheckMate 227 Part 1;3-year update: OS with NIVO + IPI vs chemo (PD-L1 ≥ 1%);3-year update: OS with NIVO + IPI vs chemo vs NIVO (PD-L1 ≥ 1%);3-year update: OS with NIVO + IPI vs Chemo vs NIVO + Chemo (PD-L1 < 1%);3-year update: PFSa among patients with PD-L1 ≥ 1% or < 1%;3-year update: ORRa and DORa among patients with PD-L1 ≥ 1% or < 1%;Exploratory landmark analysis: impact of response category on long-term OS;Post-landmark OS in responders (CR or PR) at 6 monthsa;Post-landmark OS in patients with stable disease at 6 monthsa;Post-landmark OS in patients with progressive disease at 6 monthsa;Safety summary: NIVO + IPI, chemo, NIVO, NIVO + chemo;Treatment-related select adverse events over time: NIVO + IPI;Summary: NIVO + IPI in first-line advanced NSCLC;Acknowledgments;Investigators;Abbreviations;QR Code

文档评论(0)

qingfengxulai + 关注
实名认证
内容提供者

文档来源于网络

1亿VIP精品文档

相关文档